Literature DB >> 10873919

Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients.

A Anand1, P Verhoeff, N Seneca, S S Zoghbi, J P Seibyl, D S Charney, R B Innis.   

Abstract

OBJECTIVE: Increased dopaminergic neurotransmission has been implicated in the pathophysiology of bipolar disorder. However, it remains unclear whether the abnormality is due to increased dopamine release or enhanced postsynaptic receptor sensitivity. In this study, dopamine receptor imaging combined with a pharmacological challenge of amphetamine was used to assess both pre- and postsynaptic aspects of dopamine neurotransmission in euthymic bipolar disorder patients.
METHOD: Thirteen patients with bipolar disorder (seven medication free and six receiving mood stabilizer therapy) who had been euthymic for more than 4 weeks and 13 age- and gender-matched healthy comparison subjects were included in the study. Single photon emission computed tomography scans were obtained with the striatal dopamine (D(2)/D(3)) receptor radiotracer iodobenzamide ([(123)I]IBZM) before and after an intravenous amphetamine challenge (0.3 mg/kg). Reduction in striatal [(123)I]IBZM binding potential from the first scan to the second scan was used as an indirect measure of the amount of dopamine released. Behavioral response to amphetamine was measured with the Brief Psychiatric Rating Scale, Young Mania Rating Scale, and visual analogue scales.
RESULTS: Bipolar patients and healthy subjects did not differ in terms of mood state or striatal D(2) receptor binding at baseline. Amphetamine challenge led to a significantly greater behavioral response in bipolar patients than in healthy subjects. However, there was no significant difference between the two groups in the amphetamine-induced decrease in striatal [(123)I]IBZM binding.
CONCLUSIONS: In a group of euthymic patients with bipolar disorder, this study did not find evidence for increased striatal dopamine release. Instead, these data are consistent with enhanced postsynaptic dopamine responsivity in patients with bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873919     DOI: 10.1176/appi.ajp.157.7.1108

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  42 in total

Review 1.  The behavioral activation system and mania.

Authors:  Sheri L Johnson; Michael D Edge; M Kathleen Holmes; Charles S Carver
Journal:  Annu Rev Clin Psychol       Date:  2011-11-07       Impact factor: 18.561

2.  Chronic valproate treatment blocks D2-like receptor-mediated brain signaling via arachidonic acid in rats.

Authors:  Epolia Ramadan; Mireille Basselin; Ameer Y Taha; Yewon Cheon; Lisa Chang; Mei Chen; Stanley I Rapoport
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

3.  Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

Review 4.  Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.

Authors:  Zuowei Wang; David E Kemp; Philip K Chan; Yiru Fang; Stephen J Ganocy; Joseph R Calabrese; Keming Gao
Journal:  Int J Neuropsychopharmacol       Date:  2010-09-29       Impact factor: 5.176

Review 5.  Positron emission tomography molecular imaging in late-life depression.

Authors:  Kentaro Hirao; Gwenn S Smith
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-01-05       Impact factor: 2.680

6.  Sex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [¹¹C]raclopride.

Authors:  Nina B L Urban; Lawrence S Kegeles; Mark Slifstein; Xiaoyan Xu; Diana Martinez; Ehab Sakr; Felipe Castillo; Tiffany Moadel; Stephanie S O'Malley; John H Krystal; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2010-08-03       Impact factor: 13.382

Review 7.  The psychopathology and treatment of bipolar disorder.

Authors:  David J Miklowitz; Sheri L Johnson
Journal:  Annu Rev Clin Psychol       Date:  2006       Impact factor: 18.561

Review 8.  Dysregulation of the behavioral approach system (BAS) in bipolar spectrum disorders: review of theory and evidence.

Authors:  Snezana Urosević; Lyn Y Abramson; Eddie Harmon-Jones; Lauren B Alloy
Journal:  Clin Psychol Rev       Date:  2008-05-09

9.  Effects of mood stabilizers on DNA damage in an animal model of mania.

Authors:  Ana Cristina Andreazza; Marcia Kauer-Sant'Anna; Benicio N Frey; Laura Stertz; Caroline Zanotto; Leticia Ribeiro; Karine Giasson; Samira S Valvassori; Gislaine Z Réus; Mirian Salvador; João Quevedo; Carlos A Gonçalves; Flavio Kapczinski
Journal:  J Psychiatry Neurosci       Date:  2008-11       Impact factor: 6.186

10.  Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?

Authors:  Paul J Fitzgerald; Chris Barkus; Michael Feyder; Lisa M Wiedholz; Yi-Chyan Chen; Rose-Marie Karlsson; Rodrigo Machado-Vieira; Carolyn Graybeal; Trevor Sharp; Carlos Zarate; Judith Harvey-White; Jing Du; Rolf Sprengel; Peter Gass; David Bannerman; Andrew Holmes
Journal:  Neurobiol Dis       Date:  2010-08-08       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.